gastric%20cancer
GASTRIC CANCER
Gastric cancer is the cancer originating in the esophagus, esophagogastric junction and stomach.
Most of gastric cancers are adenocarcinomas, subdivided according to histological appearances into diffuse (undifferentiated) and intestinal (well differentiated) types.
It is the 4th most common cancer and the 2nd most common cause of cancer-related deaths worldwide.
Most common sites of gastric cancer are the proximal lesser curvature, cardia and esophagogastric junction.

Introduction

  • Fourth most common cancer & second most common cause of cancer-related deaths worldwide
    • In Japan, this is the most common type of cancer in men
  • Most common sites of gastric cancer are the proximal lesser curvature, cardia & esophagogastric junction

Definition

  • Cancers originating in the esophagus, esophagogastric junction & stomach
  • Most of gastric cancers (90%) are adenocarcinomas, subdivided according to histological appearances into diffuse (undifferentiated) & intestinal (well-differentiated) types (Lauren classification)

Signs and Symptoms

  • Early stage gastric cancer rarely causes symptoms
    • Most commonly diagnosed at an advanced stage
  • Dyspepsia is the early stage symptom
  • Advanced stage signs & symptoms include:
    • Poor appetite
    • Weight loss
    • Dysphagia
    • Abdominal pain
    • Vague abdominal discomfort, usually above the navel
    • A sense of fullness in the upper abdomen after eating a small meal (early satiety)
    • Heartburn or indigestion
    • Nausea & vomiting
    • Swelling or fluid build-up in the abdomen
    • Iron-deficiency anemia

Risk Factors

  • Male
  • Old age (>50 years old)
  • Helicobacter pylori infection
    • Usually the major cause
  • Cigarette/tobacco use
  • Previous gastric surgery eg partial gastrectomy
  • Menetrier’s disease or hypertrophic gastropathy
  • Atrophic gastritis
  • Diet that has large amounts of smoked foods, salted fish & meat & pickled vegetables
    • Nitrates & nitrites on these foods have shown to produce bacteria that causes cancer
  • Stomach lymphoma
  • Pernicious anemia
  • Type A blood
  • Overweight or obesity
  • Inherited cancer syndromes (3-5%) eg hereditary diffuse gastric cancer, hereditary non-polyposis colorectal cancer, familial adenomatous polyposis, breast cancer, Li-Fraumeni syndrome, Peutz-Jeghers syndrome
  • Family history of stomach cancer (5-10%)
  • Epstein-Barr virus
  • Certain occupations eg coal, metal & rubber industry workers
  • Common variable immune deficiency
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Saras Ramiya, 4 days ago
Accord Healthcare launches Accord Bortezomib® (bortezomib 3.5 mg per vial) for the treatment of patients with multiple myeloma and mantle cell lymphoma in Malaysia.
Dr. Alexander Drilon, 19 Jul 2017
With the dramatic evolution of sequencing technology and emergence of effective targeted therapies, using a comprehensive molecular approach to guide treatment decisions is becoming more accessible and applicable in the clinic. At the recent Foundation Medicine meeting in Hong Kong, Dr Alexander Drilon, clinical director of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center (MSKCC), New York, US, discussed the current landscape and potential benefits of comprehensive molecular profiling in non-small cell lung cancer (NSCLC).
31 Jan 2017
At the launch of Caris Molecular Intelligence® in Malaysia, Dr Andrew Dean, Head of Oncology at the St John of God Subianco Hospital, Perth, shared with the audience on molecular profiling and its benefits, with a focus on the Caris Molecular Intelligence® service.
Su Ping Chuah, 01 Aug 2014

New immune therapies with new targets that can induce long-term remission in patients with advanced cutaneous T-cell lymphoma (CTCL) are needed, says an expert.